Orforglipron's safety and effectiveness in adults with mild overweight and fat-related health problems

Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, is being evaluated for its effects on body weight and cardiometabolic parameters in adults with a body mass index (BMI) of 27 to <30 kg/m².

• The phase 3 ATTAIN-1 trial demonstrated improvements in body weight and cardiometabolic parameters with Orforglipron.
• Adults with a BMI of 27 to <30 kg/m² and adiposity-related complications face significant cardiometabolic risks.
• There is a recommendation for obesity medications for this population to address their health risks.
• The efficacy and safety of Orforglipron in this specific group have not yet been fully characterized.

Simplified